Production of OspA for Lyme Disease Control
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Apr 9, 2009
filing date -
Apr 9, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of Borrelia burgdorferi.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully